RAFA Stock Overview
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rafarma Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.10 |
| 52 Week High | US$0.43 |
| 52 Week Low | US$0.10 |
| Beta | 0 |
| 1 Month Change | -39.61% |
| 3 Month Change | -61.57% |
| 1 Year Change | -70.45% |
| 3 Year Change | -95.41% |
| 5 Year Change | 183.33% |
| Change since IPO | -95.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| RAFA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.0% | 0.9% | 1.2% |
| 1Y | -70.5% | 13.9% | 24.7% |
Return vs Industry: RAFA underperformed the US Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: RAFA underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| RAFA volatility | |
|---|---|
| RAFA Average Weekly Movement | 18.3% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RAFA's share price has been volatile over the past 3 months.
Volatility Over Time: RAFA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | rafarma.si |
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders.
Rafarma Pharmaceuticals, Inc. Fundamentals Summary
| RAFA fundamental statistics | |
|---|---|
| Market cap | US$8.95m |
| Earnings (TTM) | -US$117.22k |
| Revenue (TTM) | US$133.33k |
0.0x
P/S Ratio0.0x
P/E RatioIs RAFA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RAFA income statement (TTM) | |
|---|---|
| Revenue | US$133.33k |
| Cost of Revenue | US$133.33k |
| Gross Profit | US$0 |
| Other Expenses | US$117.22k |
| Earnings | -US$117.22k |
Last Reported Earnings
Mar 31, 2012
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did RAFA perform over the long term?
See historical performance and comparison